Mineralys Therapeutics (MLYS) Competitors $16.03 -0.16 (-0.99%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock MLYS vs. ZLAB, PTCT, CYTK, RNA, KRYS, SRPT, MRUS, ACLX, ACAD, and SWTXShould you be buying Mineralys Therapeutics stock or one of its competitors? The main competitors of Mineralys Therapeutics include Zai Lab (ZLAB), PTC Therapeutics (PTCT), Cytokinetics (CYTK), Avidity Biosciences (RNA), Krystal Biotech (KRYS), Sarepta Therapeutics (SRPT), Merus (MRUS), Arcellx (ACLX), ACADIA Pharmaceuticals (ACAD), and SpringWorks Therapeutics (SWTX). These companies are all part of the "pharmaceutical products" industry. Mineralys Therapeutics vs. Zai Lab PTC Therapeutics Cytokinetics Avidity Biosciences Krystal Biotech Sarepta Therapeutics Merus Arcellx ACADIA Pharmaceuticals SpringWorks Therapeutics Mineralys Therapeutics (NASDAQ:MLYS) and Zai Lab (NASDAQ:ZLAB) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their community ranking, dividends, analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment and valuation. Is MLYS or ZLAB more profitable? Mineralys Therapeutics has a net margin of 0.00% compared to Zai Lab's net margin of -76.14%. Zai Lab's return on equity of -36.97% beat Mineralys Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Mineralys TherapeuticsN/A -67.97% -62.40% Zai Lab -76.14%-36.97%-27.10% Does the MarketBeat Community prefer MLYS or ZLAB? Zai Lab received 211 more outperform votes than Mineralys Therapeutics when rated by MarketBeat users. However, 90.91% of users gave Mineralys Therapeutics an outperform vote while only 64.53% of users gave Zai Lab an outperform vote. CompanyUnderperformOutperformMineralys TherapeuticsOutperform Votes2090.91% Underperform Votes29.09%Zai LabOutperform Votes23164.53% Underperform Votes12735.47% Which has stronger valuation & earnings, MLYS or ZLAB? Mineralys Therapeutics has higher earnings, but lower revenue than Zai Lab. Zai Lab is trading at a lower price-to-earnings ratio than Mineralys Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMineralys TherapeuticsN/AN/A-$177.81M-$3.73-4.32Zai Lab$418.33M10.52-$334.62M-$2.49-16.02 Do institutionals and insiders believe in MLYS or ZLAB? 84.5% of Mineralys Therapeutics shares are held by institutional investors. Comparatively, 41.7% of Zai Lab shares are held by institutional investors. 25.6% of Mineralys Therapeutics shares are held by insiders. Comparatively, 5.0% of Zai Lab shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Do analysts recommend MLYS or ZLAB? Mineralys Therapeutics currently has a consensus price target of $38.00, indicating a potential upside of 135.88%. Zai Lab has a consensus price target of $47.37, indicating a potential upside of 18.75%. Given Mineralys Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Mineralys Therapeutics is more favorable than Zai Lab.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mineralys Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Zai Lab 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75 Does the media refer more to MLYS or ZLAB? In the previous week, Zai Lab had 5 more articles in the media than Mineralys Therapeutics. MarketBeat recorded 7 mentions for Zai Lab and 2 mentions for Mineralys Therapeutics. Mineralys Therapeutics' average media sentiment score of 1.28 beat Zai Lab's score of 0.99 indicating that Mineralys Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mineralys Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zai Lab 4 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility & risk, MLYS or ZLAB? Mineralys Therapeutics has a beta of -0.17, indicating that its share price is 117% less volatile than the S&P 500. Comparatively, Zai Lab has a beta of 0.96, indicating that its share price is 4% less volatile than the S&P 500. SummaryMineralys Therapeutics beats Zai Lab on 9 of the 16 factors compared between the two stocks. Get Mineralys Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MLYS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MLYS vs. The Competition Export to ExcelMetricMineralys TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.03B$6.86B$5.58B$8.64BDividend YieldN/A2.50%5.27%4.19%P/E Ratio-4.348.9127.3720.17Price / SalesN/A263.74414.23164.07Price / CashN/A65.8538.2534.64Price / Book4.136.697.164.72Net Income-$177.81M$143.74M$3.23B$247.88M7 Day Performance-1.95%11.78%6.50%4.30%1 Month Performance8.29%20.94%15.27%10.63%1 Year Performance17.52%9.61%32.69%14.87% Mineralys Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MLYSMineralys Therapeutics2.769 of 5 stars$16.01-1.1%$38.00+137.4%+23.2%$1.04BN/A-4.3928Positive NewsZLABZai Lab1.7227 of 5 stars$37.87-0.6%$47.37+25.1%+89.4%$4.18B$418.33M-13.671,950Positive NewsPTCTPTC Therapeutics3.198 of 5 stars$51.69-0.8%$63.75+23.3%+41.5%$4.10B$1.77B-8.701,410Analyst RevisionCYTKCytokinetics4.0628 of 5 stars$33.13+2.6%$70.92+114.1%-37.2%$3.96B$19.22M-6.16250Analyst ForecastAnalyst RevisionRNAAvidity Biosciences2.2241 of 5 stars$32.66-9.9%$67.62+107.0%+22.8%$3.94B$8.93M-11.34190Trending NewsAnalyst ForecastHigh Trading VolumeKRYSKrystal Biotech4.5719 of 5 stars$136.08-0.6%$211.13+55.1%-17.2%$3.93B$333.45M45.51210Analyst RevisionSRPTSarepta Therapeutics4.8487 of 5 stars$39.71-7.7%$122.61+208.8%-67.8%$3.90B$2.23B31.77840High Trading VolumeMRUSMerus2.9244 of 5 stars$54.91-2.3%$85.83+56.3%+3.8%$3.80B$54.73M-13.9037ACLXArcellx2.0519 of 5 stars$66.86-1.8%$111.33+66.5%+31.7%$3.75B$76.81M-94.1780Positive NewsAnalyst RevisionACADACADIA Pharmaceuticals3.5959 of 5 stars$22.30+1.5%$26.79+20.1%+49.8%$3.73B$996.28M28.59510Analyst RevisionSWTXSpringWorks Therapeutics1.5144 of 5 stars$46.75-0.1%$52.57+12.5%+16.2%$3.52B$219.67M-13.43230Positive NewsHigh Trading Volume Related Companies and Tools Related Companies ZLAB Competitors PTCT Competitors CYTK Competitors RNA Competitors KRYS Competitors SRPT Competitors MRUS Competitors ACLX Competitors ACAD Competitors SWTX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MLYS) was last updated on 6/10/2025 by MarketBeat.com Staff From Our PartnersBanks aren’t ready for this altcoin—are you?Donald Trump just fast-tracked TWO major crypto bills with an August deadline! Your window of opportunity i...Crypto 101 Media | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsA major regulatory shift is scheduled to take effect this July — and it could have serious implications for yo...Monetary Gold | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored“Biggest Social Security Change Ever”The Financial Times called this new Trump initiative "a big pot of money for the American people." And The Mot...InvestorPlace | SponsoredTrump’s Secret WeaponThe Trump-Elon War Could Trigger an Economic Collapse - Here's Your Only Safe Exit This isn't just a war of...American Alternative | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mineralys Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Mineralys Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy MLYS Stock Free MLYS Stock Alerts